A
$ Value
—
Shares
8,170
Price
—
Filed
Feb 26
Insider
Name
Coste Catherine
Title
—
CIK
0001821432
Roles
Director
Transaction Details
Transaction Date
2026-02-24
Code
A
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
13,871
Footnotes
The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026.
Filing Info
Coste Catherine's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-24 | BLFS | A | — |
Other Insiders at BLFS (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
DE GREEF RODERICK
President and CEO
|
— | — | 2026-03-19 |
| GOSWAMI JOYDEEP | — | — | 2026-02-24 |
|
Mathew Aby J.
EVP & Chief Scientific Officer
|
— | $11K | 2026-04-08 |
| Ellingson Rachel | — | — | 2026-02-24 |
| Hunt Anthony | — | — | 2026-02-24 |
|
Berard Todd
Chief Marketing Officer
|
— | $7K | 2026-04-08 |
| MOORE TIMOTHY L. | — | — | 2026-02-24 |
|
Foster Karen A.
Chief Quality and Operations
|
— | $2.0M | 2026-03-23 |
|
Aebersold Sarah
Chief Human Resources Officer
|
— | $5K | 2026-03-19 |
| DuRoss Amy | — | — | 2026-02-24 |
|
Wichterman Troy
Chief Financial Officer
|
— | $12K | 2026-04-08 |
|
Werner Sean
Chief Technology Officer
|
— | $2K | 2026-03-19 |